Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Event, Product/Service

Endeavor BioMedicines to Present New Data From Phase 2a Clinical Trial of ENV-101 at American Thoracic Society 2024 International Conference

Endeavor BioMedicines, a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, announced that data from a completed Phase 2a clinical trial evaluating the company's lead investigational candidate ENV-101 in patients with idiopathic pulmonary fibrosis (IPF) will be presented for the first time in a late-breaking oral session at the American Thoracic Society 2024 (ATS 2024) International Conference. ATS 2024 will take place May 17-22, 2024, in San Diego.

The Phase 2a, randomized, double-blind, placebo-controlled clinical trial (NCT04968574) evaluated the safety and efficacy of ENV-101 vs. placebo in 41 patients with confirmed IPF who were treated for 12 weeks.

Following are details about the ENV-101 oral presentation at ATS 2024:

"We look forward to sharing the results from the Phase 2a trial of ENV-101 with the pulmonology community for the first time at ATS 2024," said Paul A. Frohna, M.D., Ph.D., Pharm.D., Chief Medical Officer, Endeavor BioMedicines. "There is a tremendous need for new therapies that have the potential to reverse lung fibrosis and improve lung function in patients with IPF, and these data suggest ENV-101 could be an important new option for patients."

ENV-101 blocks a cellular wound-healing pathway known as Hedgehog (Hh) that is abnormally activated in fibrotic lung diseases such as IPF and causes the buildup of scar tissue in the lungs. Current standard-of-care therapies do not address the underlying cause of IPF. They slow the decline of lung function, but do not stop or reverse it, and they have tolerability issues that limit their long-term use in most patients. Based on results from the Phase 2a trial of ENV-101, Endeavor BioMedicines intends to initiate a Phase 2 trial in patients with IPF and in a parallel cohort, patients with progressive pulmonary fibrosis (PPF), in 2024.

About Idiopathic Pulmonary Fibrosis
IPF is a chronic, progressive lung disease that affects more than 100,000 adults in the United States. Although the exact cause of IPF is unknown, various environmental factors can deliver repeated injuries to lung cells that trigger abnormal wound-healing processes and life-threatening lung scarring. IPF is a chronic disease with limited treatment options and a very poor prognosis: the average life expectancy is only three to five years after diagnosis.

About ENV-101
Endeavor BioMedicines' investigational medicine ENV-101 is a Hedgehog signaling pathway inhibitor. By binding to and inhibiting a key receptor in the Hedgehog pathway, ENV-101 stops the abnormal accumulation of the myofibroblasts that cause fibrosis. This may resolve the excessive wound-healing process seen in IPF and PPF, creating the potential to reverse fibrosis and improve lung volume and function.

About Endeavor BioMedicines
Endeavor BioMedicines is a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases. Endeavor's lead candidate, ENV-101, is an inhibitor of the Hedgehog signaling pathway in clinical development for the treatment of IPF and PPF. The company's second candidate, ENV-501, is a HER3 antibody-drug conjugate (ADC) for the treatment of HER3-positive solid tumors. More information is available at www.endeavorbiomedicines.com and on LinkedIn or X.

These press releases may also interest you

at 08:03
GL0034 administered once-weekly confirmed clinically meaningful weight loss and improved gluco-metabolic parameters over a 4-week treatment period in individuals with obesity, even in the lowest dosing regimen.GL0034 demonstrated gluco-metabolic...

at 08:01
NeuroBo Pharmaceuticals, Inc. , a clinical-stage biotechnology company focused on the transformation of cardiometabolic diseases, today announced pre-clinical data which indicates that DA-1726, a novel, dual oxyntomodulin (OXM) analog...

at 08:00
Today, findings from INHALE-3, a pivotal trial examining the use of inhaled insulin in adults with type 1 diabetes (T1D), were announced, highlighting the potential of an alternative insulin solution to enhance diabetes management. The results were...

at 07:00
The prestigious 2024 Tang Prize Laureates have been announced, recognizing outstanding contributions in various fields. The Tang Prize in Sustainable Development is awarded to American chemist Omar M. Yaghi. In the field of Biopharmaceutical Science,...

at 05:01
GreenTree Hospitality Group Ltd. ("GreenTree" or the "Company"), a leading hospitality management group in China, today announced that it will report its unaudited financial results for the first quarter ended March 31, 2024, on Tuesday June 25,...

21 jun 2024
BodyHealth's strawberry flavored PERFECT AMINOtm dietary supplement has...

News published on and distributed by: